Meeting
2016 ASCO Annual Meeting
Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study.
Authors
Anna Spreafico
Princess Margaret Cancer Centre, Toronto, ON, Canada
Anna Spreafico , Eric Chen , Solmaz Sahebjam , Daniel John Renouf , Karen Kelly , Albert C. Lockhart , Ulka N. Vaishampayan , Sebastien J. Hotte , Albiruni R. Razak , Lisa Wang , Lee-Anne Stayner , Alanna Bougie , Helen X. Chen , S. Percy Ivy , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02070549
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2578)
DOI
10.1200/JCO.2016.34.15_suppl.2578
Abstract #
2578
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients (pts) with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).
First Author: A. M. Traynor
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang